Management of Phantom Limb Pain and Sensation with Milnacipran

A 77-year-old man with an above-knee amputation on his right leg for arteriosclerosis obliterans was transferred to the department of orthopedics for the purpose of right hip disarticulation due to osteomyelitis in the amputation stump. On the 11th day after the operation, he was referred to the department of psychiatry because he developed paroxysmal phantom limb pain “squeezed” in the absent right knee and ankle joint. Simultaneously, the patient experienced a phantom limb sensation as if the “amputated right lower extremity was actually present.” He was not depressive, anxious, or hypochondriacal. He was administered 100 mg/day of fluvoxamine for 3 years after the first operation to treat depressive symptoms. Other therapy included 25 mg/day of quetiapine for delirium and 0.5 mg/day of etizolam for sleep disturbances after the last operation. Milnacipran, 30 mg/day, was added to the regimen. The abnormal pain and sensation were reduced after 1 week but did not vanish. The dosage of milnacipran was increased to 50 mg/day in order to reach remission. After 3 weeks of milnacipran therapy, the phantom limb pain and sensation completely disappeared without adverse events. He continued to take 50 mg/day of milnacipran and was discharged without relapse.

In our case, milnacipran rather than fluvoxamine was likely successful in the management of phantom limb pain and sensation because these phenomena developed abruptly during the long-term administration of fluvoxamine and there was rapid dose-dependent improvement following administration of milnacipran. There is a significant amount of evidence to show that tricyclic antidepressants have analgesic efficacy against different kinds of pain due to their action on noradrenergic and serotonergic systems in descending inhibitory pain pathways. 3 Although several reports suggest that selective serotonin reuptake inhibitors (SSRIs) are also capable of alleviating neuropathic pain, meta-analysis found that tricyclic antidepressants showed outstanding analgesic efficacy as compared with SSRIs. 4 Therefore, reuptake inhibition of both 5-HT and noradrenaline arguably play an important role in analgesic efficacy. Milnacipran would reveal a prominent analgesic effect by selectively inhibiting the reuptake of both 5-HT and noradrenaline. 5 In addition, our patient experienced no adverse events. Milnacipran is devoid of affinity for various neuroreceptors associated with numerous adverse events. 5 From a clinical point of view, with respect to pharmacodynamic characteristics, milnacipran could be expected to have tolerability and a therapeutic effect for phantom limb pain and sensation.